Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99Tc-MDP versus celecoxib for high-metabolism lumbar degenerative disease with chronic low back pain
ChiCTR1900024919Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Dec 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of technetium-99m-methylene diphosphonate and celecoxib in lumbar intervertebral disc degenerative disease (LDDD) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Pain relief rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
technetium-99m-methylene diphosphonatecelecoxib
03
Conditions
lumbar intervertebral disc degenerative disease (LDDD)
Beyond the preview
Go deeper on ChiCTR1900024919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024919.